Search Results - "Belch, Andrew"

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report by Palumbo, Antonio, Bringhen, Sara, Mateos, Maria-Victoria, Larocca, Alessandra, Facon, Thierry, Kumar, Shaji K., Offidani, Massimo, McCarthy, Philip, Evangelista, Andrea, Lonial, Sagar, Zweegman, Sonja, Musto, Pellegrino, Terpos, Evangelos, Belch, Andrew, Hajek, Roman, Ludwig, Heinz, Stewart, A. Keith, Moreau, Philippe, Anderson, Kenneth, Einsele, Hermann, Durie, Brian.G.M., Dimopoulos, Meletios A., Landgren, Ola, San Miguel, Jesus F., Richardson, Paul, Sonneveld, Pieter, Rajkumar, S. Vincent

“…We conducted a pooled analysis of 869 individual newly diagnosed elderly patient data from 3 prospective trials. At diagnosis, a geriatric assessment had been…”
Get full text

Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma by Benboubker, Lotfi, Dimopoulos, Meletios A, Dispenzieri, Angela, Catalano, John, Belch, Andrew R, Cavo, Michele, Pinto, Antonello, Weisel, Katja, Ludwig, Heinz, Bahlis, Nizar, Banos, Anne, Tiab, Mourad, Delforge, Michel, Cavenagh, Jamie, Geraldes, Catarina, Lee, Je-Jung, Chen, Christine, Oriol, Albert, de la Rubia, Javier, Qiu, Lugui, White, Darrell J, Binder, Daniel, Anderson, Kenneth, Fermand, Jean-Paul, Moreau, Philippe, Attal, Michel, Knight, Robert, Chen, Guang, Van Oostendorp, Jason, Jacques, Christian, Ervin-Haynes, Annette, Avet-Loiseau, Hervé, Hulin, Cyrille, Facon, Thierry

“…In patients ineligible for transplantation, the combination of lenalidomide and dexamethasone with lenalidomide maintenance until disease progression achieved…”
Get full text

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial by Miguel, Jesus San, Prof, Weisel, Katja, MD, Moreau, Philippe, MD, Lacy, Martha, MD, Song, Kevin, MD, Delforge, Michel, MD, Karlin, Lionel, MD, Goldschmidt, Hartmut, MD, Banos, Anne, MD, Oriol, Albert, MD, Alegre, Adrian, MD, Chen, Christine, MD, Cavo, Michele, MD, Garderet, Laurent, MD, Ivanova, Valentina, MD, Martinez-Lopez, Joaquin, MD, Belch, Andrew, MD, Palumbo, Antonio, MD, Schey, Stephen, MD, Sonneveld, Pieter, MD, Yu, Xin, PhD, Sternas, Lars, MD, Jacques, Christian, MD, Zaki, Mohamed, MD, Dimopoulos, Meletios, MD

“…Summary Background Few effective treatments exist for patients with refractory or relapsed and refractory multiple myeloma not responding to treatment with…”
Get full text

Skeletal muscle radio-density is an independent predictor of response and outcomes in follicular lymphoma treated with chemoimmunotherapy by Chu, Michael P, Lieffers, Jessica, Ghosh, Sunita, Belch, Andrew R, Chua, Neil S, Fontaine, Amelie, Sangha, Randeep, Turner, A Robert, Baracos, Vickie E, Sawyer, Michael B

“…Skeletal muscle radio-density (SMD) measures muscle radiation attenuation (in Hounsfield Units, HU) on computed tomography (CT) scans. Low SMD is prognostic of…”
Get full text

MS4A4A: a novel cell surface marker for M2 macrophages and plasma cells by Sanyal, Ratna, Polyak, Maria J, Zuccolo, Jonathan, Puri, Mandip, Deng, Lili, Roberts, Luc, Zuba, Ania, Storek, Jan, Luider, Joanne M, Sundberg, Ellen M, Mansoor, Adnan, Baigorri, Eva, Chu, Michael P, Belch, Andrew R, Pilarski, Linda M, Deans, Julie P

“…MS4A4A is a member of the membrane‐spanning, four domain family, subfamily A (MS4A) that includes CD20 (MS4A1), FcRβ (MS4A2) and Htm4 (MS4A3). Like the first…”
Get full text

Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma by MARCUS, Robert, IMRIE, Kevin, WASSNER-FRITSCH, Elisabeth, STEIN, George, SOLAL-CELIGNY, Philippe, CATALANO, John V, DMOSZYNSKA, Anna, RAPOSO, Joao C, OFFNER, Fritz C, GOMEZ-CODINA, José, BELCH, Andrew, CUNNINGHAM, David

“…To compare the long-term outcome of patients with previously untreated follicular lymphoma (FL) needing therapy, after treatment with cyclophosphamide,…”
Get full text

The systemic cytokine environment is permanently altered in multiple myeloma by Zheng, Mary M, Zhang, Zhifang, Bemis, Kyle, Belch, Andrew R, Pilarski, Linda M, Shively, John E, Kirshner, Julia

“…Multiple myeloma (MM) is an incurable bone marrow malignancy of the B cell lineage. Utilizing multiplex Luminex technology we measured levels of 25 cytokines…”
Get full text

Single-Cell Analysis and Next-Generation Immuno-Sequencing Show That Multiple Clones Persist in Patients with Chronic Lymphocytic Leukemia by Kriangkum, Jitra, Motz, Sarah N, Mack, Tanner, Beiggi, Sara, Baigorri, Eva, Kuppusamy, Hemalatha, Belch, Andrew R, Johnston, James B, Pilarski, Linda M

“…The immunoglobulin heavy chain (IGH) gene rearrangement in chronic lymphocytic leukemia (CLL) provides a unique molecular signature; however, we demonstrate…”
Get full text

Blockade of fatty acid synthase triggers significant apoptosis in mantle cell lymphoma by Gelebart, Pascal, Zak, Zoulika, Anand, Mona, Belch, Andrew, Lai, Raymond

“…Fatty acid synthase (FASN), a key player in the de novo synthetic pathway of long-chain fatty acids, has been shown to contribute to the tumorigenesis in…”
Get full text

Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN‐003/MYX.1 single arm phase II trial by Venner, Christopher P., LeBlanc, Richard, Sandhu, Irwindeep, White, Darrell, Belch, Andrew R., Reece, Donna E., Chen, Christine, Dolan, Sean, Lalancette, Marc, Louzada, Martha, Kew, Andrea, McCurdy, Arleigh, Monteith, Bethany, Reiman, Tony, McDonald, Gail, Sherry, Max, Gul, Engin, Chen, Bingshu E., Hay, Annette E.

“…The MCRN‐003/CCTGMYX.1 is a single arm phase II trial of weekly carfilzomib, cyclophosphamide and dexamethasone (wKCd), exploring a convenient immunomodulator…”
Get full text

A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma by Kirshner, Julia, Thulien, Kyle J., Martin, Lorri D., Debes Marun, Carina, Reiman, Tony, Belch, Andrew R., Pilarski, Linda M.

“…Although the in vitro expansion of the multiple myeloma (MM) clone has been unsuccessful, in a novel three-dimensional (3-D) culture model of reconstructed…”
Get full text

Impact of Age on Outcomes After Initial Therapy With Chemotherapy and Different Chemoimmunotherapy Regimens in Patients With Chronic Lymphocytic Leukemia: Results of Sequential Cancer and Leukemia Group B Studies by WOYACH, Jennifer A, RUPPERT, Amy S, LARSON, Richard A, BYRD, John C, RAI, Kanti, LIN, Thomas S, GEYER, Susan, KOLITZ, Jonathan, APPELBAUM, Frederick R, TALLMAN, Martin S, BELCH, Andrew R, MORRISON, Vicki A

“…Chronic lymphocytic leukemia (CLL) is a disease of the elderly, yet few clinical trials include a significant number of older patients, and outcomes after…”
Get full text

Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma by LEVY, Ronald, GANJOO, Kristen N, NICHOLS, Craig, EMMANOUILIDES, Christos E, TIMMERMAN, John M, GREGORY, Stephanie A, LINK, Brian K, INWARDS, David J, FREEDMAN, Arnold S, MATOUS, Jeffrey V, ROBERTSON, Michael J, KUNKEL, Lori A, LEONARD, John P, INGOLIA, Diane E, GENTLES, Andrew J, CHIH LONG LIU, TIBSHIRANI, Robert, ALIZADEH, Ash A, DENNEY, Dan W, VOSE, Julie M, FLINN, Ian W, AMBINDER, Richard F, CONNORS, Joseph M, BERINSTEIN, Neil L, BELCH, Andrew R, BARTLETT, Nancy L

“…Idiotypes (Ids), the unique portions of tumor immunoglobulins, can serve as targets for passive and active immunotherapies for lymphoma. We performed a…”
Get full text

Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index by Chung, Randy, Lai, Raymond, Wei, Peter, Lee, Jason, Hanson, John, Belch, Andrew R., Turner, A. Robert, Reiman, Tony

“…In diffuse large B-cell lymphoma (DLBCL), previous studies have suggested that, while concordant bone marrow (BM) involvement confers a poor prognosis,…”
Get full text

Alteration of introns in a hyaluronan synthase 1 (HAS1) minigene convert Pre-mRNA [corrected] splicing to the aberrant pattern in multiple myeloma (MM): MM patients harbor similar changes by Kriangkum, Jitra, Warkentin, Amanda, Warkinton, Amanda, Belch, Andrew R, Pilarski, Linda M

“…Aberrant pre-mRNA splice variants of hyaluronan synthase 1 (HAS1) have been identified in malignant cells from cancer patients. Bioinformatic analysis suggests…”
Get full text

High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program by Mikhael, Joseph R., Belch, Andrew R., Prince, H. Miles, Lucio, Maria Nambo, Maiolino, Angelo, Corso, Alessandro, Petrucci, Maria Teresa, Musto, Pellegrino, Komarnicki, Mieczyslaw, Stewart, A. Keith

“…Summary Phase 2 trials have demonstrated that bortezomib ± dexamethasone is safe and effective in relapsed multiple myeloma (MM). In this multicentre,…”
Get full text

FGFR3 preferentially colocalizes with IGH in the interphase nucleus of multiple myeloma patient B-cells when FGFR3 is located outside of CT4 by Martin, Lorri D., Harizanova, Jana, Mai, Sabine, Belch, Andrew R., Pilarski, Linda M.

“…Many B‐cell malignancies are characterized by chromosomal translocations involving IGH and a proto‐oncogene. For translocations to occur, spatial proximity of…”
Get full text

Addressing heterogeneity of individual blood cancers: the need for single cell analysis by Chu, Michael P., Kriangkum, Jitra, Venner, Christopher P., Sandhu, Irwindeep, Hewitt, Joanne, Belch, Andrew R., Pilarski, Linda M.

“…Cancer heterogeneity is a significant factor in response to treatment and escape leading to relapse. Within an individual cancer, especially blood cancers,…”
Get full text

Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study by Pfreundschuh, Michael, Prof, Ho, Anthony D, MD, Cavallin-Stahl, Eva, MD, Wolf, Max, Prof, Pettengell, Ruth, Prof, Vasova, Ingrid, MD, Belch, Andrew, MD, Walewski, Jan, MD, Zinzani, Pier-Luigi, MD, Mingrone, Walter, MD, Kvaloy, Stein, MD, Shpilberg, Ofer, Prof, Jaeger, Ulrich, Prof, Hansen, Mads, Prof, Corrado, Claudia, MD, Scheliga, Adriana, MD, Loeffler, Markus, Prof, Kuhnt, Evelyn, Dipl Math

“…Summary Background The definition and role of bulky disease in young patients (ie, aged 18–60 years) with good-prognosis diffuse large-B-cell lymphoma (DLBCL),…”
Get full text

Inherited polymorphisms in hyaluronan synthase 1 predict risk of systemic B-cell malignancies but not of breast cancer by Kuppusamy, Hemalatha, Ogmundsdottir, Helga M, Baigorri, Eva, Warkentin, Amanda, Steingrimsdottir, Hlif, Haraldsdottir, Vilhelmina, Mant, Michael J, Mackey, John, Johnston, James B, Adamia, Sophia, Belch, Andrew R, Pilarski, Linda M

“…Genetic variations in the hyaluronan synthase 1 gene (HAS1) influence HAS1 aberrant splicing. HAS1 is aberrantly spliced in malignant cells from multiple…”
Get full text